# Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

> **NCT02468284** · PHASE1 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** degarelix

## Key facts

- **NCT ID:** NCT02468284
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-10-13
- **Final completion:** 2017-10-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468284, "Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02468284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*